Award Timing Disclosure

12 Months Ended

Dec. 31, 2025

Jan. 02, 2026

USD ($)

$ / shares

Rate

Award Timing Disclosures [Line Items]

Stock option awards are approved by the Board or Compensation Committee each year in December, and, beginning with the December 2025 compensation decision cycle, are granted in January of the following year. Approval dates are normally set one year in advance based on the date of the fourth quarter Board meeting. Stock option awards may also be made to new executive officers upon hire or promotion, generally coincident with the date of hire for new executive officers or the last business day of the month in which the executive officer was promoted. While we do not maintain written policies on the timing of stock option awards, we have established processes to ensure that the timing of any stock option grants to the NEOs is not influenced by material non-public information (“MNPI”) about the Company, either positive or negative, and that all grant decisions are based on a predetermined schedule. The Compensation Committee considers factors like Company and employee performance and market conditions, regardless of any upcoming announcements or events that could impact our stock price. The Company has not timed the disclosure of MNPI for the purpose of affecting the value of executive compensation. The exercise price of options granted is equal to the closing market price of the Company’s common stock on the effective date of the grant.

The following table provides information regarding stock options granted to our NEOs in 2026 within four business days before the filing of a periodic report or current report disclosing MNPI or within one business day after the filing of such information.


Name	Grant Date	Number of securities underlying the award		Exercise price of the award ($)		Grant date fair value of the award ($)		Percentage change in the closing market price of the securities underlying the award between the trading day ending immediately prior to the disclosure of material nonpublic information and the trading day beginning immediately following the disclosure of material nonpublic information
Michael Henderson, M.D.	January 2, 2026		253,016	$	75.78	$	12,999,229	1.86%
Carl Dambkowski, M.D.	January 2, 2026		83,690	$	75.78	$	4,299,750	1.86%
Jane Pritchett Henderson	January 2, 2026		83,690	$	75.78	$	4,299,750	1.86%

(1)

On January 6, 2026, we filed a Current Report on Form 8-K announcing positive interim data from the Phase 1b clinical trial of zumilokibart (APG777) for the treatment of patients with mild-to-moderate asthma and highlighting upcoming 2026 milestones.

Award Timing Method

Award Timing Predetermined

true

Award Timing MNPI Considered

true

Award Timing, How MNPI Considered

the timing of any stock option grants to the NEOs is not influenced by material non-public information (“MNPI”) about the Company, either positive or negative, and that all grant decisions are based on a predetermined schedule.

MNPI Disclosure Timed for Compensation Value

false

Awards Close in Time to MNPI Disclosures, Table

the timing of any stock option grants to the NEOs is not influenced by material non-public information (“MNPI”) about the Company, either positive or negative

Michael Henderson, M.D.

Awards Close in Time to MNPI Disclosures

Name

Michael Henderson, M.D.

Underlying Securities | shares

253,016

Exercise Price | $ / shares

$ 75.78

Fair Value as of Grant Date | $

$ 12,999,229

Underlying Security Market Price Change | Rate

1.86%